Restricted accessResearch articleFirst published online 2016-12
Developing an Inactivated Rotavirus Vaccine and Evaluating the Immunogenicity Against a Commercially Available Attenuated Rotavirus Vaccine Using a Mice Animal Model
There is a high demand for public immunization against Rotavirus (RV), especially in Africa. In Africa, the attenuated RV vaccination is contraindicated in patients with immune diseases and nutrition deficiency. Therefore, the inactivated RV vaccine (IRVV) could be an alternative. In this study, we aimed to develop a pentavalent-IRVV using the most circulating RV strains in Egypt and evaluate it against the commercially available Rotarix® vaccine. Trial-IRVV was developed with 5% sucrose, 2% polysorbate-80, and adsorbed on Alum to potentiate the vaccine immune response. Then, it was injected subcutaneously into mice groups at 0-, 21-, and 35-time intervals. In parallel, Rotarix was administered twice on 0 and 28th day. The success of the pentavalent-IRVV/monovalent-Rotarix vaccine immunity rested on achieving immunoglobulin G (IgG) exceeding 1:6,400 that implies less susceptibility to RV infection (RVI). IRVV stimulating IgG >1:6,400 could be an alternative vaccination approach to reach a reasonable protective immunization level against RVI. In addition, Alum adjuvant incorporation effectively provoked a triple elevation of the immunization pattern.
Get full access to this article
View all access options for this article.
References
1.
AhmedSF, MansourAM, KlenaJD, et al.Rotavirus genotypes associated with acute diarrhea in Egyptian infants. Pediatr Infect Dis J, 2014; 33(Suppl. 1):S62–S68.
2.
AmerMA, Abdel-SalamSM, IbrahimHAH, et al.Detection of group A Rota virus and characterization of G type among Egyptian children with diarrhea. Egypt J Med Microbiol, 2007; 16:123–133.
3.
BishopRF, CiprianiE, LundJS, et al.Estimation of rotavirus immunoglobulin G antibodies in human serum samples by enzyme-linked immunosorbent assay: expression of results as units derived from a standatd curve. J Clin Microbiol. 1984; 19:447–452.
4.
Centers for Disease Control and prevention. Postmarketing monitoring of intussusception after RotaTeq™ vaccination—United States, February 1, 2006–February 15, 2007. MMWR Morb Mortal Wkly Rep, 2007; 56:218–222.
5.
DangiAA, ShethNR, SodhaHH, et al.Formulation and development of vaccines and their selection for next generation. Bull Pharm Res, 2011; 1:49–62.
6.
El-MohamadyH, Abdel-MessihIA, YoussefFG, et al.Enteric pathogens associated with diarrhea in children in Fayoum, Egypt. Diagn Microbiol Infect Dis, 2006; 56:1–5.
7.
FDA Briefing Document. Vaccines and related biological products advisory committee meeting. Cell lines derived from human tumors for vaccine manufacture, 2012; pp. 1–30.
8.
GrayJ, DesselbergerU. Rotaviruses: Methods and Protocols. Vol. 34. Cambridge, UK: Humana Press, 2000.
9.
GrimwoodK, and ButteryJP. Clinical update: rotavirus gastroenteritis and its prevention. Lancet, 2007; 370:302–304.
10.
Hashem S.EA, ShomanSA, ZakiSA, et al.Isolation and molecular genotyping of group A rotavirus strains circulating among Egyptian infants and children. Aust J Basic Appl Sci, 2012; 6:361–367.
11.
JiangB, EstesMK, BaroneC, et al.Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine, 1999; 17:1005–1013.
12.
JiangB, GentschJR, and GlassRI. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine, 2008; 26:6754–6758.
13.
JiangB, WangY, SaluzzoJF, et al.Immunogenicity of a thermally inactivated rotavirus vaccine in mice. Hum Vaccin, 2008; 4:143–147.
14.
JohansenK, SchröderU, and SvenssonL. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vaccine, 2003; 21:368–375.
KirkwoodCD, RoczoS, BonifaceK, et al.Australian rotavirus surveillance program annual report, 2010/11. Commun Dis Intell Q Rep, 2011; 35:281–287.
17.
LondriganSL, HewishMJ, ThomsonMJ, et al.Growth of rotaviruses in continuous human and monkey cell lines that vary in their expression of integrins. J Gen Virol, 2000; 81:2203–2213.
18.
MadhiSA, CunliffeNA, SteeleD, et al.Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med, 2010; 362:289–298.
19.
MatthijnssensJ, CiarletM, McDonaldSM, et al.Uniformity of rotavirus strain nomenclature proposed by the rotavirus classification working group (RCWG). Arch Virol, 2011; 156:1397–1413.
20.
McNealMM, RaeMN, ConnerME, et al.Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology, 1998; 243:158–166.
21.
McNealMM, RaeMN, and WardRL. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine, 1999; 17:1573–1580.
22.
MoonSS, TateJE, RayP, et al.Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. Pediatr Infect Dis J, 2013; 32; 863–870.
23.
MoonS, WangY, EdensC, et al.Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine, 2013; 31:3396–3402.
24.
MurphyTV, GargiulloPM, MassoudiMS, et al.Intussusception among infants given an oral rotavirus vaccine. N Engl J Med, 2001; 344:564–572.
25.
NaficyAB, Abu-ElyazeedR, HolmesJL, et al.Epidemiology of rotavirus diarrhea in Egyptian children and implications for disease control. Am J Epidemiol, 1999; 150:770–777.
26.
ParasharUD, GibsonCJ, BreseeJS, et al.Rotavirus and severe childhood diarrhea. Emerg Infect Dis, 2006; 12:304–306.
27.
PatelM, PedreiraC, De OliveiraLH, et al.Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in nicaragua. J Am Med Assoc, 2009; 301:2243–2251.
28.
PatelM, ShaneAL, ParasharUD, et al.Oral rotavirus vaccines: how well will they work, where they are needed most?. J Infect Dis, 2009; 200(Suppl. 1): S39–S48.
29.
PetrovskyN, and AguilarJC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol, 2004; 82:488–496.
30.
PintoRM, DiezJM, and BoschA. Use of the colonic carcinoma cell line CaCo-2 for in vivo amplification and detection of enteric viruses. J Med Virol, 1994; 44:310–315.
31.
PizzaM, GiulianiMM, FontanaMR, et al.Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine, 2001; 19:2534–2541.
32.
RadwanSF, GabrMK, El-MaraghiS, et al.Serotyping of group A rotaviruses in Egyptian neonates and infants less than 1 year old with acute diarrhea. J Clin Microbiol, 1997; 35:2996–2998.
33.
RainsfordEW, and McCraeMA. Characterization of the NSP6 protein product of rotavirus gene 11. Virus Res, 2007; 130:193–201.
34.
ReedSG, BertholetS, ColerRN, et al.New horizons in adjuvants for vaccine development. Trends Immunol, 2009; 30:23–32.
35.
RheingansRD, AntilL, DreibelbisR, et al.Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis, 2009; 200(Supp1):S16–S27.
36.
Ruiz-PalaciosGM, Pérez-SchaelI, VelázquezFR, et al.Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med, 2006; 354:11–22.
37.
SantosN, and HoshinoY. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol, 2005; 15:29–56.
38.
SatoK, InabaY, ShinozakiT, et al.Isolation of human rotavirus in cell cultures. Arch Virol, 1981; 69:155–160.
39.
SmithEM, EstesMK, GrahamDY, et al.A plaque assay for the simian rotavirus SAII. J Gen Virol, 1979; 43:513–519.
40.
TuckerAW, HaddixAC, BreseeJS, et al.Cost-effectiveness analysis of a rotavirus immunization program for the United States. J Am Med Assoc, 1998; 279:1371–1376.
41.
UrasawaT, UrasawaS, and TaniguchiK. Sequential passages of human rotavirus in MA-104 cells. Microbiol Immunol, 1981; 25:1025–1035.
42.
VelázquezFR, MatsonDO, CalvaJJ, et al.Rotavirus infection in infants as protection against subsequent infections. N Engl J Med, 1996; 335:1022–1028.
43.
VelázquezFR, MatsonDO, GuerreroML, et al.Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis, 2000; 182:1602–1609.
44.
VillenaC, El-SenousyWM, AbadFX, et al.Group A rotavirus in sewage samples from Barcelona and Cairo: emergence of unusual genotypes. Appl Environ Microbiol, 2003; 69:3919–3923.
45.
WangY, AzevedoM, SaifLJ, et al.Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine, 2010; 28:5432–5436.
46.
WHO expert committee on biological standarization. Requirements for the use of animal cells as in vitro substrates for the production of biologicals. WHO Tech Rep Series, 1998; 878:19–56.
47.
WierzabaTF, Abdel-MessihIA, Abu-ElyazeedR, et al.Clinic-based surveillance for bacterial- and Rotavirus-associated diarrhea in Egyptian children. Am J Trop Med Hyg, 2006; 74:148–153.
48.
YuanL, KangSY, WardLA, et al.Antibody-secreting cell responses and protective immunity assessed in gnotobiotic pigs inoculated orally or intramuscularly with inactivated human rotavirus. J Virol, 1998; 72:330–338.
49.
ZamanK, DangDA, VictorJC, et al.Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet, 2010; 376:615–623.
50.
ZhangB, YiS, MaY, et al.Immunogenicity of a scalable inactivated rotavirus vaccine in mice. Hum Vaccin, 2011; 7:248–257.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
